濾胞性リンパ腫治療薬の世界市場2018-2022

【英語タイトル】Global Follicular Lymphoma Therapeutics Market 2018-2022

Technavioが出版した調査資料(IRTNTR23892)・商品コード:IRTNTR23892
・発行会社(調査会社):Technavio
・発行日:2018年10月20日
・ページ数:105
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥740,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、濾胞性リンパ腫治療薬の世界市場について調査・分析し、市場概要、市場環境、濾胞性リンパ腫治療薬市場規模、分子種類別(生物学的、小分子)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。主な分析対象企業は、Bayer, Biogen, F. Hoffmann-La Roche, Gilead, Merckなどです。
・エグゼクティブサマリー
・調査範囲・調査手法
・濾胞性リンパ腫治療薬の世界市場概要
・濾胞性リンパ腫治療薬の世界市場環境
・濾胞性リンパ腫治療薬の世界市場動向
・濾胞性リンパ腫治療薬の世界市場規模
・濾胞性リンパ腫治療薬の世界市場:業界構造分析
・濾胞性リンパ腫治療薬の世界市場:分子種類別(生物学的、小分子)
・濾胞性リンパ腫治療薬の世界市場:地域別市場規模・分析
・濾胞性リンパ腫治療薬の北米市場規模・予測
・濾胞性リンパ腫治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・濾胞性リンパ腫治療薬のアジア太平洋市場規模・予測
・濾胞性リンパ腫治療薬の主要国分析
・濾胞性リンパ腫治療薬の世界市場:意思決定フレームワーク
・濾胞性リンパ腫治療薬の世界市場:成長要因、課題
・濾胞性リンパ腫治療薬の世界市場:競争環境
・濾胞性リンパ腫治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About Follicular Lymphoma
Follicular lymphoma is a subtype of B-cell non-Hodgkin lymphoma (NHL). It is usually indolent (slow-growing) and the tumor cells grow as groups to form nodules. Symptoms of follicular lymphoma include enlarged lymph nodes, shortness of breath, fever, night sweats, and weight loss.
Technavio’s analysts forecast the Global Follicular Lymphoma Therapeutics Market to at a CAGR of 7.50% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the follicular lymphoma therapeutics market. To calculate the market size, the report considers the revenue generated from the application of follicular lymphoma therapeutics across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, follicular lymphoma therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Bayer
• Biogen
• F. Hoffmann-La Roche
• Gilead
• Merck
Market driver
• Increasing government initiatives
• For a full, detailed list, view our report

Market challenge
• High cost of treatment
• For a full, detailed list, view our report

Market trend
• Increasing patient programs
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY MOLECULE TYPE
• Segmentation by molecule type
• Comparison by molecule type
• Biologicals – Market size and forecast 2017-2022
• Small molecules – Market size and forecast 2017-2022
Market opportunity by molecule type
PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 10: CUSTOMER LANDSCAPE
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Increasing patient support programs
• Strategic alliances
• Advanced technologies
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR LANDSCAPE
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Biogen
• F. Hoffmann-La Roche
• Gilead
• Merck
PART 16: APPENDIX
• List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global NHL therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global follicular lymphoma therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global follicular lymphoma therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Late stage pipeline molecules for the treatment of follicular lymphoma
Exhibit 20: Global follicular lymphoma therapeutics market – Market share by molecule type 2017-2022 (%)
Exhibit 21: Comparison by molecule type
Exhibit 22: Global follicular lymphoma therapeutics market by biologicals – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global follicular lymphoma therapeutics market by biologicals – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global follicular lymphoma therapeutics market by small molecules – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global follicular lymphoma therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by molecule type
Exhibit 27: Global follicular lymphoma therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Follicular lymphoma therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Follicular lymphoma therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: Follicular lymphoma therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Follicular lymphoma therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: Follicular lymphoma therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: Follicular lymphoma therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Customer landscape
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bayer – Overview
Exhibit 46: Bayer – Business segments
Exhibit 47: Bayer – Organizational developments
Exhibit 48: Bayer – Geographic focus
Exhibit 49: Bayer – Segment focus
Exhibit 50: Bayer – Key offerings
Exhibit 51: Bayer – Key customers
Exhibit 52: Biogen – Overview
Exhibit 53: Biogen – Business segments
Exhibit 54: Biogen – Organizational developments
Exhibit 55: Biogen – Geographic focus
Exhibit 56: Biogen – Key offerings
Exhibit 57: Biogen – Key customers
Exhibit 58: F. Hoffmann-La Roche – Overview
Exhibit 59: F. Hoffmann-La Roche – Business segments
Exhibit 60: F. Hoffmann-La Roche – Organizational developments
Exhibit 61: F. Hoffmann-La Roche – Geographic focus
Exhibit 62: F. Hoffmann-La Roche – Segment focus
Exhibit 63: F. Hoffmann-La Roche – Key offerings
Exhibit 64: F. Hoffmann-La Roche – Key customers
Exhibit 65: Gilead – Overview
Exhibit 66: Gilead – Business segments
Exhibit 67: Gilead – Organizational developments
Exhibit 68: Gilead – Geographic focus
Exhibit 69: Gilead – Key offerings
Exhibit 70: Gilead – Key customers
Exhibit 71: Merck – Overview
Exhibit 72: Merck – Business segments
Exhibit 73: Merck – Organizational developments
Exhibit 74: Merck – Geographic focus
Exhibit 75: Merck – Segment focus
Exhibit 76: Merck – Key offerings
Exhibit 77: Merck – Key customers



【掲載企業】

Bayer, Biogen, F. Hoffmann-La Roche, Gilead, Merck

★調査レポート[濾胞性リンパ腫治療薬の世界市場2018-2022] (コード:IRTNTR23892)販売に関する免責事項を必ずご確認ください。
★調査レポート[濾胞性リンパ腫治療薬の世界市場2018-2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆